Skip to content
Clinical Trials – home

Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o.

Research site

Poland Ul. Marcelinska 42, 60-354 Poznan, Poland

  • 18 trials recruiting
  • Endocrine ophthalmopathy · Type 2 diabetes mellitus · Chronic kidney disease
  • Adults and children

About Specializations

Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o. in Poznan, Poland specialises in clinical trials of conditions such as Endocrine ophthalmopathy, Type 2 diabetes mellitus, Chronic kidney disease, Obesity, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Research

At Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o. in Poznan, cardiology research focuses on cardiovascular diseases, especially atherosclerotic cardiovascular disease and elevated lipoprotein(a). These studies are designed to evaluate whether new treatments can lower major heart-related risks and improve long-term outcomes.

  • Cardiovascular disease and elevated lipoprotein(a)
  • Preventing coronary heart disease events and related complications
  • Testing therapies that may reduce heart attack and revascularization risk

This area reflects a strong interest in improving prevention and treatment strategies for people at high cardiovascular risk.

Kidney and Metabolic Disease Studies

The site also supports research in nutritional and metabolic diseases and metabolism, with a major emphasis on chronic kidney disease, high proteinuria, obesity, and metabolic dysfunction-associated steatotic liver disease. The trials are mainly aimed at slowing disease progression, protecting kidney function, and improving overall metabolic health.

  • Chronic kidney disease with hypertension or high proteinuria
  • Obesity and overweight linked to metabolic disease
  • Metabolic dysfunction-associated steatotic liver disease

These studies explore whether newer treatment combinations can better preserve kidney function and support broader cardiometabolic care.

Gastroenterology and Immune-Mediated Disease Research

A substantial part of the research portfolio covers digestive system diseases and immune system diseases, especially Crohn’s disease and ulcerative colitis. The trials are focused on improving symptom control, achieving remission, and strengthening long-term disease management for patients with inflammatory bowel disease.

  • Crohn’s disease, including moderately to severely active forms
  • Ulcerative colitis and treatment maintenance
  • Evaluating combinations and newer therapies for better clinical outcomes

This research area highlights efforts to refine treatment effectiveness while also addressing quality of life in chronic intestinal inflammation.

Endocrine and Autoimmune Disorders

The site participates in studies of hormonal diseases and related autoimmune conditions, including Graves’ disease, thyroid eye disease, and classic congenital adrenal hyperplasia. These trials are designed to assess whether emerging therapies can better control hormone imbalance, reduce disease activity, and support more stable long-term management.

  • Thyroid eye disease and eye-related autoimmune inflammation
  • Graves’ disease and maintenance of normal thyroid function
  • Congenital adrenal hyperplasia and adrenal hormone control

This therapeutic area combines endocrine care with autoimmune research, reflecting a broad effort to improve outcomes in complex hormone-related disorders.

Diabetes and Broader Metabolic Care

Research at this hospital/clinic also includes type 1 diabetes and related metabolic conditions. The main goal is to evaluate treatment options that may improve glycaemic control and make diabetes management more effective and practical for patients living with long-term metabolic disease.

  • Type 1 diabetes and blood sugar control
  • Supporting better day-to-day metabolic management
  • Comparing new approaches with established insulin-based care

These studies add to the site’s wider focus on metabolism and chronic disease care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Marcelinska 4260-354 PoznanPoland
Recruiting now
18 trials
Conditions studied
15

More sites in PoznanPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

27 clinical trials

Obesity+1

Recruiting

A Phase III Study of Lenbelintide in Adults with Obesity or Overweight and Weight‑Related Comorbidity Without Type 2 Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

A Phase III Randomized Double‑Blind Study of Elecoglipron for Adults with Type 2 Diabetes on Insulin

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A Phase III Study of Elecoglipron Compared with Semaglutide for Adults with Type 2 Diabetes Mellitus

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Recordati AG

Obesity

Recruiting

Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

AMG 732 in Patients With Thyroid Eye Disease Who Did Not Respond or Relapsed After Previous Treatment

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AMG 732
  • Sponsor:Amgen Inc.

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

A study of LY4268989 and mirikizumab in adults with moderately to severely active ulcerative colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.